06 May 2013 | News | By BioSpectrum Bureau
Singapore: Janssen Pharma, which is member of the Johnson&Johnson (J&J) group of companies, South Korean unit has been ordered to stop manufacturing of two types of children's Tylenol syrup, according to the The Korea Times.
Janssen was asked to shut down its manufacturing unit as it was found to have violated manufacturing regulations. The move comes one week after J&J recalled all 170 batches of cherry-flavored children's dye-free Tylenol suspension because some bottles contained a higher concentration of the active ingredient, acetaminophen, than specified on the label and can cause liver damage.
The drug manufacturer faces up to six months of production suspension for violating rules, according to the Korean Ministry of Food and Drug Safety.